Skip to main content

Evaluating the impact of public health notification: Duke clopidogrel experience.

Publication ,  Journal Article
Eisenstein, EL; Wojdyla, D; Anstrom, KJ; Brennan, JM; Califf, RM; Peterson, ED; Douglas, PS
Published in: Circ Cardiovasc Qual Outcomes
November 2012

BACKGROUND: Provider and public health interventions in the late 2006 sought to change the duration of clopidogrel use after drug-eluting stent (DES) implantation. We evaluated whether public health interventions were associated with changes in patient-reported clopidogrel use among DES patients. METHODS AND RESULTS: We used interrupted time analyses to evaluate trends in duration of patient-reported clopidogrel use before, during, and after public and provider interventions. We included patients with significant coronary artery disease receiving an intracoronary stent between April 2004 and December 2007 at a single tertiary care center. The center supplemented national and regulatory messaging regarding the role of clopidogrel after DES implantation with direct-to-patient and to-their-provider notifications in December 2006. The combination of public and provider direct notification was associated with significant changes in the percent of DES patients reporting clopidogrel use at 6 months (16.55% increase, P=0.010) and 12 months (15.33% increase, P=0.004), but no change at 24-month follow-up (4.64, P=0.295). During the same period, there was no change in the percent of bare-metal stent patients reporting clopidogrel use at 6-month (-3.73%, 0.654), 12-month (-5.98%, P=0.389), and 24-month follow-up (-5.16, P=0.708). Although mortality rates through 24 months seemed to decrease between the pre- and postintervention periods, these changes were not significant (DES, P=0.086; bare-metal stent, P=0.296). CONCLUSIONS: The combination of national scientific and regulatory messaging supplemented by local, personal communications to DES patients and their primary healthcare providers was associated with a significant increase in patient-reported clopidogrel use.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

November 2012

Volume

5

Issue

6

Start / End Page

767 / 774

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Stents
  • Registries
  • Public Health Informatics
  • Prosthesis Design
  • Proportional Hazards Models
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Eisenstein, E. L., Wojdyla, D., Anstrom, K. J., Brennan, J. M., Califf, R. M., Peterson, E. D., & Douglas, P. S. (2012). Evaluating the impact of public health notification: Duke clopidogrel experience. Circ Cardiovasc Qual Outcomes, 5(6), 767–774. https://doi.org/10.1161/CIRCOUTCOMES.111.963330
Eisenstein, Eric L., Daniel Wojdyla, Kevin J. Anstrom, J Matthew Brennan, Robert M. Califf, Eric D. Peterson, and Pamela S. Douglas. “Evaluating the impact of public health notification: Duke clopidogrel experience.Circ Cardiovasc Qual Outcomes 5, no. 6 (November 2012): 767–74. https://doi.org/10.1161/CIRCOUTCOMES.111.963330.
Eisenstein EL, Wojdyla D, Anstrom KJ, Brennan JM, Califf RM, Peterson ED, et al. Evaluating the impact of public health notification: Duke clopidogrel experience. Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):767–74.
Eisenstein, Eric L., et al. “Evaluating the impact of public health notification: Duke clopidogrel experience.Circ Cardiovasc Qual Outcomes, vol. 5, no. 6, Nov. 2012, pp. 767–74. Pubmed, doi:10.1161/CIRCOUTCOMES.111.963330.
Eisenstein EL, Wojdyla D, Anstrom KJ, Brennan JM, Califf RM, Peterson ED, Douglas PS. Evaluating the impact of public health notification: Duke clopidogrel experience. Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):767–774.

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

November 2012

Volume

5

Issue

6

Start / End Page

767 / 774

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Stents
  • Registries
  • Public Health Informatics
  • Prosthesis Design
  • Proportional Hazards Models
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention